[1]于亚静,杨彩哲,刘明,等.BRAFV600E在甲状腺乳头状癌与桥本甲状腺炎相关性中的研究[J].国际内分泌代谢杂志,2014,(06):375-378.[doi:10.3760/cma.j.issn.1673-4157.2014.06.004]
　Yu Yajing,Yang Caizhe,Liu ming,et al.Study of BRAFV600E in the correlation between papillary thyroid carcinoma and Hashimoto’s thyroiditis[J].International Journal of Endocrinology and Metabolism,2014,(06):375-378.[doi:10.3760/cma.j.issn.1673-4157.2014.06.004]
点击复制

BRAFV600E在甲状腺乳头状癌与桥本甲状腺炎相关性中的研究()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
期数:
2014年06期
页码:
375-378
栏目:
论著
出版日期:
2014-12-20

文章信息/Info

Title:
Study of BRAFV600E in the correlation between papillary thyroid carcinoma and Hashimoto’s thyroiditis
作者:
于亚静; 杨彩哲; 刘明; 任力; 王良宸; 曹亚蕊
100142 北京,空军总医院内分泌科
Author(s):
Yu Yajing; Yang Caizhe; Liu ming; Ren Li; Wang Liangchen; Cao Yarui.
Department of Endocrinology, Air Force General Hospital,Beijing 100142,China
关键词:
甲状腺乳头状癌;  桥本甲状腺炎;  BRAFV600E
Keywords:
Thyroid papillary carcinoma;  Hashimoto’s thyroiditis;  BRAFV600E
DOI:
10.3760/cma.j.issn.1673-4157.2014.06.004
摘要:
目的 研究BRAFV600E在甲状腺乳头状癌与桥本甲状腺炎中的表达,探讨甲状腺乳头状癌与桥本甲状腺炎的相关性。方法 北京空军总医院2012年1月—2014年6月经病理证实的甲状腺石蜡标本,甲状腺乳头状癌40例、桥本甲状腺炎20例、甲状腺乳头状癌伴桥本甲状腺炎20例、甲状腺腺瘤20例,采用免疫组化(Envision法)检测BRAFV600E的表达并进行半定量分析,比较其在各组中的表达差异。结果 甲状腺乳头状癌BRAFV600E阳性率为77.5%(31/40),桥本甲状腺炎BRAFV600E阳性率为45.0%(9/20,P=0.012)。甲状腺乳头状癌伴桥本甲状腺炎的肿瘤组织区域BRAFV600E阳性率为70.0%(14/20),与单纯甲状腺乳头状癌的阳性率差异无统计学意义(P=0.156); 而桥本甲状腺炎区域BRAFV600E阳性率为55%(11/20,P=0.527),与单纯桥本甲状腺炎BRAFV600E的阳性率差异亦无统计学意义(P>0.05)。甲状腺乳头状癌有转移者BRAFV600E阳性率(88.2%,15/17)高于甲状腺乳头状癌未转移者(69.5%,16/23,P=0.030)。甲状腺腺瘤中未检测到BRAFV600E。结论 甲状腺乳头状癌和桥本甲状腺炎均呈现较高的BRAFV600E突变率。
Abstract:
Objective To explore the expression of BRAFV600E in papillary thyroid carcinoma and Hashimoto’s thyroiditis, and investigate the correlation between papillary thyroid carcinoma and Hashimoto’s thyroiditis. Methods The paraffin embedded tissue specimens of pathologically confirmed thyroid disease during 2012.1-2014.6 in the Air Force General Hospital were collected, including 40 cases of papillary thyroid carcinoma, 20 cases of Hashimoto’s thyroiditis, 20 cases of papillary thyroid carcinoma with Hashimoto’s thyroiditis and 20 cases of thyroid adenoma. Immunohistochemistry(Envision method)was used to detect the expression of BRAFV600E and semi quantitative analysis was used to compare the difference of different thyroid diseases. Results The positive rate of BRAFV600E was 77.5%(31/40)in papillary thyroid carcinoma and 45%(9/20)in Hashimoto’s thyroiditis(P=0.012).In papillary thyroid carcinoma with Hashimoto’s thyroiditis, the positive rate of BRAFV600E in thyroid papillary carcinoma tissue was 70.0%(14/20), which was not different from thyroid papillary carcinoma(P=0.156); and the positive rate of BRAFV600E in Hashimoto’s thyroiditis tissue was 55.0%(11/20),which was not different from Hashimoto’s thyroiditis(P=0.527).The positive rate of BRAFVE600 in metastatic papillary thyroid carcinoma was 88.2%(15/17), which was higher than that in papillary thyroid carcinoma without metastasis(69.5%,16/23, P=0.030).There was no expression of BRAFV600E in thyroid adenoma. Conclusion Papillary thyroid carcinoma and Hashimoto’s thyroiditis have a higher BRAFV600E mutation rate.

参考文献/References:

[1] Enewold L,Zhu K,Ron E,et al.Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005[J].Cancer Epidemiol Biomarkers Prev,2009,18(3):784-791.
[2] Paulson LM,Shindo ML,Schuff KG.Role of chronic lymphocytic thyroiditis in central node metastasis of papillary thyroid carcinoma[J].Otolaryngol Head Neck Surg,2012,147(3):444-449.
[3] He G,Zhao B,Zhang X,et al.Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma[J].Oncol Lett,2014,7(2):439-443.
[4] 江晓燊,解乃昌.甲状腺乳头状癌BRAFV600E突变蛋白质的表达及意义[J].广东医学,2013,34(6):931-933.
[5] Sclafani F,Gonzalez D,Cunningham D, et al.RAS mutations and cetuximab in locally advanced rectal Cancer: results of the EXPERT-C trial[J].Eur J Cancer,2014,50(8):1430-1436.
[6] Gibault L,Cazes A,Narjoz C, et al.Molecular profiling of non-small cell lung cancer[J].Rev Pneumol Clin,2014,70(1-2):47-62.
[7] Kebebew E,Weng J,Bauer J,et al.The prevalence and prognostic value of BRAF mutation in thyroid cancer[J].Ann Surg,2007,246(3):466-470; discussion 470-471.
[8] Xing M.BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications[J].Endocr Rev,2007,28(7):742-762.
[9] Franzoni A,Dima M,D’agostino M,et al.Prohibitin is overexpressed in papillary thyroid carcinomas bearing the BRAF(V600E)mutation[J].Thyroid,2009,19(3):247-255.
[10] Faustino A,Couto JP,Pópulo H, et al.mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma[J].J Clin Endocrinol Metab,2012,97(7):E1139-E1149.
[11] 闫慧娴,谷伟军,杨国庆,等.桥本甲状腺炎与甲状腺乳头状癌关系的临床研究[J].中华内分泌代谢杂志,2014,30(4):302-306.
[12] Marotta V,Guerra A,Zatelli MC,et al.BRAF mutation positive papillary thyroid carcinoma is less advanced when Hashimoto’s thyroiditis lymphocytic infiltration is present[J].Clin Endocrinol(Oxf),2013,79(5):733-738.
[13] Jeong JS,Kim HK,Lee CR, et al.Coexistence of chronic lymphocytic thyroiditis with papillary thyroid carcinoma: clinical manifestation and prognostic outcome[J].J Korean Med Sci,2012,27(8):883-889.
[14] Kim TH,Park YJ,Lim JA,et al.The association of the BRAF(V600E)mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis[J].Cancer,2012,118(7):1764-1773.

相似文献/References:

[1]贾媛媛,陈莉丽.Th17细胞与Graves病及桥本甲状腺炎[J].国际内分泌代谢杂志,2014,(05):344.[doi:10.3760/cma.j.issn.1673-4157.2014.05.016]
　Jia Yuanyuan,Chen Lili.Relationship between Th17 cells and Graves' disease,Hashimoto's thyroiditis[J].International Journal of Endocrinology and Metabolism,2014,(06):344.[doi:10.3760/cma.j.issn.1673-4157.2014.05.016]
[2]柴锦燕,方佩华,谭建,等.定量检测人甲状腺过氧化物酶抗体 化学发光酶免疫分析法的临床应用[J].国际内分泌代谢杂志,2016,36(01):24.[doi:10.3760/cma.j.issn.1673-4157.2016.01.006]
　Chai Jinyan,Fang Peihua,Tan Jian,et al.Clinical application of chemiluminescence enzyme immunoassay to quantitatively detect human thyroid peroxidase antibodies[J].International Journal of Endocrinology and Metabolism,2016,36(06):24.[doi:10.3760/cma.j.issn.1673-4157.2016.01.006]
[3]周秦毅,陈隽,冯嘉麟,等.TM7SF4对人甲状腺乳头状癌细胞IHH-4 增殖、凋亡和侵袭的作用研究[J].国际内分泌代谢杂志,2016,36(04):241.[doi:10.3760/cma.j.issn.1673-4157.2016.04.08]
　Zhou Qinyi,Chen Jun,Feng Jialin,et al.Effects of TM7SF4 on proliferation, apoptosis and invasion of human papillary thyroid cancer IHH-4 cells[J].International Journal of Endocrinology and Metabolism,2016,36(06):241.[doi:10.3760/cma.j.issn.1673-4157.2016.04.08]
[4]房方,卫红艳,王坤玲,等.硒治疗自身免疫性甲状腺疾病的荟萃分析[J].国际内分泌代谢杂志,2016,36(04):247.[doi:10.3760/cma.j.issn.1673-4157.2016.04.09]
　Fang Fang,Wei Hongyan,Wang Kunling,et al.A meta-analysis of selenium in the treatment of autoimmune thyroid diseases[J].International Journal of Endocrinology and Metabolism,2016,36(06):247.[doi:10.3760/cma.j.issn.1673-4157.2016.04.09]
[5]党红转,徐书杭,王建华,等.颈部淋巴结转移与甲状腺乳头状癌的治疗及预后[J].国际内分泌代谢杂志,2016,36(04):277.[doi:10.3760/cma.j.issn.1673-4157.2016.04.16]
　Dang Hongzhuan*,Xu Shuhang,Wang Jianhua,et al.Treatment and prognosis of papillary thyroid cancer with cervical lymph node metastasis[J].International Journal of Endocrinology and Metabolism,2016,36(06):277.[doi:10.3760/cma.j.issn.1673-4157.2016.04.16]
[6]郑仁东,刘超.白细胞介素-6与甲状腺疾病[J].国际内分泌代谢杂志,2016,36(05):352.[doi:10.3760/cma.j.issn.1673-4157.2016.05.18]
　Zheng Rendong,Liu Chao.Interleukin-6 and thyroid disease[J].International Journal of Endocrinology and Metabolism,2016,36(06):352.[doi:10.3760/cma.j.issn.1673-4157.2016.05.18]
[7]郑慧娟,魏璠,魏军平.自噬与自身免疫性甲状腺疾病[J].国际内分泌代谢杂志,2017,37(01):17.[doi:10.3760/cma.j.issn.1673-4157.2017.01.05]
　Zheng Huijuan,Wei Fan,Wei Junping..Autophagy and autoimmune thyroid disease[J].International Journal of Endocrinology and Metabolism,2017,37(06):17.[doi:10.3760/cma.j.issn.1673-4157.2017.01.05]
[8]郑应麟 周希 杨治芳.SOCS1对CD4+T细胞分化的影响及其 在桥本甲状腺炎中的作用[J].国际内分泌代谢杂志,2018,38(05):293.[doi:10.3760/cma.j.issn.1673-4157.2018.05.002]
　Zheng Yinglin,Zhou Xi,Yang Zhifang.Effects of SOCS1 on CD4+T cell differentiation and its role in Hashimoto's thyroiditis[J].International Journal of Endocrinology and Metabolism,2018,38(06):293.[doi:10.3760/cma.j.issn.1673-4157.2018.05.002]
[9]张玉洁 孟召伟 章明放 宋丽丽 李宁.甲状腺疾病的代谢组学研究现状[J].国际内分泌代谢杂志,2019,39(03):173.[doi:10.3760/cma.j.issn.1673-4157.2019.03.007]
　Zhang Yujie,Meng Zhaowei,Zhang Mingfang,et al.Research status of metabolomics in thyroid diseases[J].International Journal of Endocrinology and Metabolism,2019,39(06):173.[doi:10.3760/cma.j.issn.1673-4157.2019.03.007]
[10]徐婷,吴丹,胡翠宁,等.甲状腺乳头状癌的淋巴结转移预测模型建立[J].国际内分泌代谢杂志,2021,41(06):596.[doi:10.3760/cma.j.cn121383-20200826-08042]
　Xu Ting,Wu Dan,Hu Cuining,et al.Construction of a risk-scoring model to predict lymph node metastasis in papillary thyroid carcinoma[J].International Journal of Endocrinology and Metabolism,2021,41(06):596.[doi:10.3760/cma.j.cn121383-20200826-08042]

更新日期/Last Update: 2014-12-20